Trial Profile
The effects of early conversion from calcineurin inhibitors to Rapamune [sirolimus] on the development of chronic allograft nephropathy compared to unit protocol (conversion to mycophenolate mofetil)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2005
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 22 Jul 2005 New trial record.